Background & relevance

mCRPC is a heterogeneous disease with diverse drivers of progression and mechanisms of therapeutic resistance. New therapeutic agents for mCRPC are (being) developed based on increasing knowledge about the biology of PCa and the availability of next-generation sequencing tools to identify genetic alterations.

Regulatory approval status of drugs for mCRPC discussed in this topic (indications limited to the mCRPC setting; status 4 April 2023)